Abstract
Anticholinergic drug use is on the rise. In England, there is evidence that anticholinergic burden of patients, particularly older people in care and nursing homes, increased markedly during the COVID-19 pandemic. The UK medicines regulator is also considering extending access to the anticholinergic bladder drug oxybutynin over the counter, despite major concerns over its link […]
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
